Sensus Healthcare (NASDAQ:SRTS – Get Free Report) and Spectral AI (NASDAQ:MDAI – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.
Volatility & Risk
Sensus Healthcare has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Spectral AI has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500.
Earnings & Valuation
This table compares Sensus Healthcare and Spectral AI”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sensus Healthcare | $27.48 million | 1.91 | -$7.72 million | ($0.47) | -6.79 |
| Spectral AI | $19.65 million | 4.34 | -$7.57 million | ($0.53) | -5.06 |
Spectral AI has lower revenue, but higher earnings than Sensus Healthcare. Sensus Healthcare is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
25.3% of Sensus Healthcare shares are owned by institutional investors. Comparatively, 67.1% of Spectral AI shares are owned by institutional investors. 10.2% of Sensus Healthcare shares are owned by insiders. Comparatively, 13.7% of Spectral AI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Sensus Healthcare and Spectral AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sensus Healthcare | -34.50% | -15.79% | -14.02% |
| Spectral AI | -85.58% | N/A | -72.97% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Sensus Healthcare and Spectral AI, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sensus Healthcare | 1 | 1 | 5 | 0 | 2.57 |
| Spectral AI | 1 | 0 | 1 | 0 | 2.00 |
Sensus Healthcare currently has a consensus target price of $6.88, indicating a potential upside of 115.52%. Spectral AI has a consensus target price of $3.00, indicating a potential upside of 11.94%. Given Sensus Healthcare’s stronger consensus rating and higher possible upside, equities analysts clearly believe Sensus Healthcare is more favorable than Spectral AI.
Summary
Sensus Healthcare beats Spectral AI on 8 of the 13 factors compared between the two stocks.
About Sensus Healthcare
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
About Spectral AI
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
